<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L452R;E484Q;D614G literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L452R;E484Q;D614G</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Pseudotyped viruses for B.1.617 was 2.3-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay.<br/>The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617. [details on the convalescent patient sera collection are not abundantly clear in the preprint] (<a href="https://doi.org/10.1101/2021.05.14.444076" class="lit_link">Tada et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="transmissibility">Transmissibility</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> The combination caused a 3-fold increase in infectivity relative to D614G wild type. [compare to 3.5x for L452R alone] (<a href="https://doi.org/10.1101/2021.05.14.444076" class="lit_link">Tada et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Pseudotyped viruses for B.1.617 was 4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay.<br/>Neutralization by 3 Moderna vaccine sera 28 days post-booster was 5-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.617 was caused by the L452R and E484Q mutation, based on results from viruses pseudotyped for individual variants within B.1.617.<br/> (<a href="https://doi.org/10.1101/2021.05.14.444076" class="lit_link">Tada et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 1.4x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
